AICO Global Files Provisional Patent for AI Agent System Transforming Clinical Trial Operations, June 14, 2025
AICO Global has submitted a provisional patent application to the United States Patent and Trademark Office (USPTO) for its artificial intelligent agent system for clinical trial operations management. This filing marks a major milestone in advancing AI solutions for the healthcare industry.
The invention introduces an AI agent system purpose-built to replace manual, fragmented processes across clinical trial operations. Combining a large language model (LLM) fine-tuned on biopharmaceutical industry data with domain-specific retrieval-augmented generation (RAG) and integrated guardrails, the system can:
- Ingest clinical trial documents, industry practices, regulatory requirements, and prior communications
- Transform inputs into actionable institutional knowledge
- Execute cross-functional trial tasks with efficiency and accuracy
- Escalate low-confidence or high-risk cases to human experts
The system features a closed-loop learning cycle, enabling continuous refinement and evolution into a fully configured engine for end-to-end clinical operations, delivering faster, more reliable trial management.
“This provisional patent marks a major step toward our mission of revolutionizing clinical trial operations through AI,” said Bing Wang, PhD – Cofounder.
Bing Wang, PhD
Cofounder
AICO Global
Leave a Reply